New 'Living Drug' trial offers hope for kids with tough brain cancers
NCT ID NCT07390539
Summary
This early-stage study is testing a new type of personalized cell therapy called B7-H3 CAR T cells in children and young adults whose brain tumors have come back or gotten worse. The main goals are to find a safe dose and see if the body can successfully make the treatment. Participants will have their own immune cells collected, genetically modified to target a protein on their tumor, and then infused back into their body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.